Why the Market Dipped But QuickLogic Gained Today
| 46817MAS6 | 102.71 0.00 0.00% |
About 56% of 46817MAS6's investor base is looking to short. The analysis of the overall prospects from investing in JXN 567 08 JUN 32 suggests that many traders are, at the present time, alarmed. The current market sentiment, together with 46817MAS6's historical and current headlines, can help investors time the market. In addition, many technical investors use JXN 567 08 bond news signals to limit their universe of possible portfolio assets.
46817MAS6 |
The latest trading day saw QuickLogic settling at 8.57, representing a 1.9 percent change from its previous close.
Read at finance.yahoo.com
 |
JXN 567 08 Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 46817MAS6 bond to make a market-neutral strategy. Peer analysis of 46817MAS6 could also be used in its relative valuation, which is a method of valuing 46817MAS6 by comparing valuation metrics with similar companies.
Peers
46817MAS6 Related Equities
| REGN | Regeneron Pharmaceuticals | 7.81 | ||||
| CPRX | Catalyst Pharmaceuticals | 2.68 | ||||
| VALN | Valneva SE | 1.41 | ||||
| CAH | Cardinal Health | 0.65 | ||||
| APGE | Apogee Therapeutics, | 1.38 | ||||
| SSVRF | Summa Silver | 9.09 |
Other Information on Investing in 46817MAS6 Bond
46817MAS6 financial ratios help investors to determine whether 46817MAS6 Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 46817MAS6 with respect to the benefits of owning 46817MAS6 security.